Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Rheumatology Unit, Sahlgrenska University Hospital, Göteborg, Sweden.
Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118689. doi: 10.1016/j.bbamcr.2020.118689. Epub 2020 Feb 21.
The non-activating allosteric modulator AZ1729, specific for free fatty acid receptor 2 (FFAR2), transfers the orthosteric FFAR2 agonists propionate and the P2YR specific agonist ATP into activating ligands that trigger an assembly of the neutrophil superoxide generating NADPH-oxidase. The homologous priming effect on the propionate response and the heterologous receptor cross-talk sensitized ATP response mediated by AZ1729 are functional characteristics shared with Cmp58, another non-activating allosteric FFAR2 modulator. In addition, AZ1729 also turned Cmp58 into a potent activator of the superoxide generating neutrophil NADPH-oxidase, and in agreement with the allosteric modulation concept, the effect was reciprocal in that Cmp58 turned AZ1729 into a potent activating allosteric agonist. The activation signals down-stream of FFAR2 when stimulated by the two interdependent allosteric modulators were biased in that, unlike for orthosteric agonists, the two complementary modulators together triggered an activation of the NADPH-oxidase, but not any transient rise in the cytosolic concentration of free calcium ions (Ca). Furthermore, following AZ1729/Cmp58 activation, the signaling by the desensitized FFAR2s was functionally selective in that the orthosteric agonist propionate could still induce a transient rise in intracellular Ca. The novel neutrophil activation and receptor down-stream signaling pattern mediated by the two cross-sensitizing allosteric FFAR2 modulators represent a new regulatory mechanism that controls receptor signaling.
非激活型变构调节剂 AZ1729 特异性结合游离脂肪酸受体 2(FFAR2),将 FFAR2 的激动剂丙酸盐和 P2YR 特异性激动剂 ATP 转化为激活配体,触发中性粒细胞超氧化物生成 NADPH 氧化酶的组装。AZ1729 对丙酸盐反应的同源预激活效应和对 ATP 反应的异源受体交叉敏感化是与另一种非激活型变构 FFAR2 调节剂 Cmp58 共享的功能特征。此外,AZ1729 还将 Cmp58 转化为一种有效的超氧化物生成中性粒细胞 NADPH 氧化酶激活剂,并且与变构调节的概念一致,这种效应是相互的,即 Cmp58 将 AZ1729 转化为一种有效的激活型变构激动剂。当被两种相互依赖的变构调节剂刺激时,FFAR2 下游的激活信号偏向于,与经典激动剂不同,这两种互补调节剂一起触发 NADPH 氧化酶的激活,但不会引起细胞质游离钙离子浓度(Ca)的短暂升高。此外,在 AZ1729/Cmp58 激活后,脱敏的 FFAR2 的信号转导在功能上是有选择性的,因为经典激动剂丙酸盐仍然可以诱导细胞内 Ca 的短暂升高。这两种交叉敏感的变构 FFAR2 调节剂介导的新型中性粒细胞激活和受体下游信号转导模式代表了一种新的调节机制,控制着受体信号转导。